Dafinchi
Corcept Q1 2026 Demand Outlook and Future Sales Potential
Corcept's Q1 2026 demand outlook indicates strong underlying growth despite short-term revenue timing challenges, suggesting a positive long-term sales trajectory.
Read post
Detailed company information
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Jul 29, 2026
Earnings Transcript for 2026 - Q1Released: May 01, 2026
Earnings Transcript for 2025 - Q4Released: Feb 24, 2026
Earnings Transcript for 2025 - Q3Released: Nov 04, 2025
Earnings Transcript for 2025 - Q2Released: Aug 01, 2025
Earnings Transcript for 2025 - Q1Released: May 05, 2025
Earnings Transcript for 2024 - Q4Released: Feb 26, 2025
Earnings Transcript for 2024 - Q3Released: Oct 30, 2024
Earnings Transcript for 2024 - Q2Released: Jul 29, 2024
Earnings Transcript for 2024 - Q1Released: May 01, 2024
Earnings Transcript for 2023 - Q4Released: Feb 15, 2024
Earnings Transcript for 2023 - Q3Released: Nov 01, 2023
Earnings Transcript for 2023 - Q2Released: Aug 02, 2023
Earnings Transcript for 2023 - Q1Released: May 03, 2023
Earnings Transcript for 2022 - Q4Released: Feb 28, 2023
Earnings Transcript for 2022 - Q3Released: Nov 03, 2022
Earnings Transcript for 2022 - Q2Released: Aug 03, 2022
Earnings Transcript for 2022 - Q1Released: May 05, 2022
Earnings Transcript for 2021 - Q4Released: Feb 15, 2022
Earnings Transcript for 2021 - Q3Released: Nov 03, 2021
Earnings Transcript for 2021 - Q2Released: Jul 29, 2021
Earnings Transcript for 2021 - Q1Released: May 07, 2021
Earnings Transcript for 2020 - Q4Released: Feb 08, 2021
Earnings Transcript for 2020 - Q3Released: Nov 07, 2020
ERAS Erasca, Inc.
Corcept's Q1 2026 demand outlook indicates strong underlying growth despite short-term revenue timing challenges, suggesting a positive long-term sales trajectory.
Read postCorcept Therapeutics' April FDA meeting is pivotal to clarifying regulatory direction for relacorilant's approval, with possible pathways including resubmission, appeal, or new clinical studies based on FDA feedback and timeline implications.
Read post